Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

NCT01610284 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1147

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: BKM120
DRUG: BKM120 matching placebo

Sponsor

Novartis Pharmaceuticals